通过共享数据与生物标本提升临床癌症研究
本文由53位乳腺肿瘤学界学术研究者与患者代表撰写的特别通讯,分析注册性临床试验中数据与生物标本共享的障碍,并评估2017至2024年29项乳腺癌注册试验中生物标志物研究对药物适应症的影响,提出促进共享的四项策略。
要点
- 过去8年29项乳腺癌注册试验中,无一因生物标志物研究而限制药物获批适应症。
- 临床试验标本多由申办药企控制,已发表的生物标志物研究罕见。
- 提出学术与患者共同领导、知情同意明确共享、监管审批要求数据共享、开放标本独立研究四项策略。
核心结论
- 注册性试验的数据与生物标本共享不理想,需多方具体行动以加速临床癌症研究对患者照护质量的影响。
研究设计与样本
- 特别通讯,由53位乳腺肿瘤学界学术研究者与患者代表撰写,并评估2017至2024年29项乳腺癌注册性临床试验。
主要发现
- 临床试验参与者越来越多被要求提供组织或体液标本用于生物标志物研究,但已发表的生物标志物研究罕见。
- 2017至2024年29项乳腺癌注册研究中,无一导致生物标志物研究限制药物获批适应症。
关键数值与推荐
- 提出四项策略:建立学术与患者共同领导结构;知情同意书声明数据与标本将共享给学术界用于未来研究;将临床数据共享作为监管批准条件;允许独立研究获取标本与转化研究数据以探索疗效与毒性生物标志物。
临床怎么用
- 肿瘤内科医生在临床试验设计、知情同意和监管沟通中应推动数据与标本共享条款,促进生物标志物独立研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Molecular analyses of biospecimens collected from study participants are essential for identifying biomarkers that can tailor treatments to specific subsets of patients who are most likely to benefit. Sharing of data and biospecimens from clinical trials enables personalized, patient-centric use of cancer therapies and accelerates the development of new treatments. OBJECTIVE: To describe obstacles to sharing data and biospecimens and to propose strategies to enhance access and collaboration. EVIDENCE REVIEW: This is a Special Communication authored by 53 academic investigators and patient representatives from the breast cancer community with extensive experience in conducting clinical and translational research. The article also evaluates the impact of biomarker research on specifying responsive subpopulations in the 29 registrational clinical trials that have led to approval of a new drug for treatment of breast cancer between 2017 and 2024. FINDINGS: Clinical trial participants are increasingly asked to provide tissue and/or body fluid biospecimens for biomarker research that is typically controlled by the sponsoring pharmaceutical company, but published biomarker studies are rare. Among 29 breast cancer registrational studies reported in the past 8 years, none resulted in biomarker research that restricted a drug's approved indication. Herein, strategies to maximize the value of clinical data and biospecimens contributed by participants are proposed, thereby supporting the shared goals of the pharmaceutical industry and academia to improve patient care. These strategies include (1) establishing coleadership structures involving academia and patients in clinical trial design and conduct, (2) ensuring that informed consent forms state that data and biospecimens will be shared with academia for future research, (3) requiring the sharing of clinical data as a condition for regulatory approval, and (4) enabling access to biospecimens and translational research data for independent studies on biomarkers that may indicate drug efficacy and toxicity. CONCLUSIONS AND RELEVANCE: Data and biospecimen sharing from registrational trials has been suboptimal. Improving clinical data, biospecimens, and biospecimens' related data sharing requires concrete actions and a multidimensional stakeholder approach to accelerate the impact of clinical cancer research on the quality of patient care.
引用
- Wildiers H, Adam V, O'Reilly S, et al. Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens. JAMA Oncol. 2026. PMID: 41410930. doi:10.1001/jamaoncol.2025.5376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。